EUHEARING
Live / Allowed — Notice of allowance issued (as of 14 Apr 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 30 Apr 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99163934
- Mark type
- Stylized text
- Filed
- 30 Apr 2025
- Published for opposition
- 17 Feb 2026
- Attorney of record
- Alison M. Caless
Goods and services
- Class 005 — Pharmaceuticals: Liquid medicinal preparations for tinnitus treatment; Medicines for improvement of deafness gene; Medicinal preparations for treatment of deafness; Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations for gene therapy for the treatment of deafness; medicinal preparations for improving hearing loss; Medicinal infusions for treating hearing loss
- Class 010 — Medical apparatus: In-ear monitors for medical purposes; Ear trumpet; In-ear medicine delivery devices, namely, syringes and needles; Medical apparatus and instruments for use in surgery; Medical apparatus and instruments for surgery of the nerve associated with the auditory pathway; Surgical and medical apparatus and instruments for use in otologic microsurgery; Surgical and medical apparatus and instruments for use in general surgery; Injection syringes (syringe barrels); Injection needles; Attachments for medical injection devices to aid in controlling the depth of the injections; Attachments for medical injection devices to aid in stabilizing flow during injection of pharmaceuticals; Syringes for injections; Injection instruments with needles; Injection device for pharmaceuticals
- Class 042 — Scientific and technological services: Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Providing laboratory research services in the field of deafness gene expression; Development of gene-based medicines; Gene therapy research; Research in the field of gene editing technology; Scientific research in the nature of conducting clinical trials for others in the field of deafness treatment; Development of pharmaceuticals for cell and gene therapies; Laboratory research in the field of gene expression; Research and development services in the field of gene expression systems; Testing of pharmaceuticals for cell and gene therapies.
Owner
- Shanghai Euhearing Therapeutics Co., Ltd., Shanghai, CN
- Shanghai Euhearing Therapeutics Co., Ltd., Shanghai, CN
Prosecution history
- 14 Apr 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Feb 2026 — PUBLISHED FOR OPPOSITION
- 11 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 19 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 19 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 23 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 23 Sept 2025 — NON-FINAL ACTION E-MAILED
- 23 Sept 2025 — NON-FINAL ACTION WRITTEN
- 19 Sept 2025 — ASSIGNED TO EXAMINER
- 09 Sept 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 30 Apr 2025 — APPLICATION FILING RECEIPT MAILED
- 30 Apr 2025 — NEW APPLICATION ENTERED